Background: Morphologically identical breast carcinoma can display divergent clinical outcomes and response to therapies, withdifferences in incidence, clinical picture and mortality rates across various patient populations. This could be attributed to differences in the molecular characteristics of the carcinoma. Recently, gene expression profiling and its surrogate Immunohistochemistry (IHC) ...